Filtered By:
Condition: Congestive Heart Failure
Cancer: Cancer

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 80 results found since Jan 2013.

Importance of Considering Competing Risks in Time-to-Event Analyses: Application to Stroke Risk in a Retrospective Cohort Study of Elderly Patients With Atrial Fibrillation Original Articles
Conclusions: The incidence of death without stroke was 9-fold higher than that of stroke, leading to biased estimates of stroke risk with traditional time-to-event methods. Statistical methods that appropriately account for competing risks should be used to mitigate this bias.
Source: Circulation: Cardiovascular Quality and Outcomes - July 11, 2018 Category: Cardiology Authors: Abdel-Qadir, H., Fang, J., Lee, D. S., Tu, J. V., Amir, E., Austin, P. C., Anderson, G. M. Tags: Atrial Fibrillation, Epidemiology, Primary Prevention, Cerebrovascular Disease/Stroke Original Articles Source Type: research

Admission Rates, Time Trends, Risk Factors, and Outcomes of Ischemic and Hemorrhagic Stroke From German Nationwide Data
DISCUSSION: Despite recent advances in acute stroke care over the last decade, the percentage of stroke hospitalizations resulting in death remained unchanged. Further research is needed to determine how best to optimize stroke care pathways for multimorbid patients.PMID:36332988 | DOI:10.1212/WNL.0000000000201259
Source: Cancer Control - November 4, 2022 Category: Cancer & Oncology Authors: Dearbhla M Kelly Jannik Feld Peter M Rothwell Holger Reinecke Jeanette Koeppe Source Type: research

Predictive Risk Factors of In-Hospital Mortality Following Acute Stroke in the United States: Data from the Nationwide Inpatient Database, 2006-2010 (P02.015)
CONCLUSIONS: The rate of in-hospital mortality is relatively high following acute stroke (8.42%). We identified multiple risk factors of in-hospital mortality in acute stroke patients. The strongest risk factor is the type stroke (hemorrhagic). The present finding suggests that patients at increased risk of mortality can be identified and additional treatment for prevention might be warranted.Disclosure: Dr. Naderi has nothing to disclose. Dr. Abcede has nothing to disclose. Dr. Al-Khoury has nothing to disclose. Dr. Mozaffar has received personal compensation for activities with California Stem Cell Inc., NuFactor, Cresce...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Naderi, N., Abcede, H., Al-Khoury, L., Mozaffar, T., Jain, V. Tags: P02 Cerebrovascular Disease II Source Type: research

The PLAN score predicted death and severe disability in patients with acute ischemic stroke.
CONCLUSION The 9-item PLAN score based on data collected at hospital admission predicted death and severe disability in patients with acute ischemic stroke.PLAN score for predicting death and severe disability in patients hospitalized with acute ischemic stroke*PLAN score rangeNumber of patientsOutcomes (range)30-d mortality1-y mortalityDeath or severe disability at discharge†< 1048440.7% to 4.4%2.1% to 13%0.9% to 4.3%10 to 1224454.4% to 11%16% to 26%6.0% to 15%13 to 15126715% to 29%32% to 46%20% to 36%> 15129135% to 66%58% to 84%44% to 78%*PLAN = Preadmission comorbid conditions, Level of consciousness, ...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Rowland K Tags: Ann Intern Med Source Type: research

Roche launches new ways to use their cardiovascular tests empowering clinicians to improve diagnosis and treatment of millions of people
Basel, 28 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys ® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs) and bett er manage heart failure⁵ (NT-proBNP). Roche ' s introduction of five new intended uses for these existing, globally accepted diagnostic solutions means more people could benef...
Source: Roche Media News - April 28, 2021 Category: Pharmaceuticals Source Type: news

Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma
CONCLUSIONSSunitinib and sorafenib might be associated with an increased risk of cardiovascular events and particularly stroke. Cancer 2015. © 2015 American Cancer Society.
Source: Cancer - October 6, 2015 Category: Cancer & Oncology Authors: Sekwon Jang, Chaoyi Zheng, Huei‐Ting Tsai, Alex Z. Fu, Ana Barac, Michael B. Atkins, Andrew N. Freedman, Lori Minasian, Arnold L. Potosky Tags: Original Article Source Type: research

The Association of Arsenic Metabolism with Cancer, Cardiovascular Disease, and Diabetes: A Systematic Review of the Epidemiological Evidence
Conclusions: Population level of iAs% and DMA%, but not MMA%, were associated with arsenic exposure levels. Overall, study findings suggest that higher MMA% was associated with an increased risk of cancer and cardiovascular disease, while lower MMA% was associated with an increased risk of diabetes and metabolic syndrome. Additional population-based studies and experimental studies are needed to further evaluate and understand the role of arsenic exposure in arsenic metabolism and the role of arsenic metabolism in disease development. https://doi.org/10.1289/EHP577 Received: 01 June 2016 Revised: 26 February 2017 Acce...
Source: EHP Research - August 2, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Anticoagulant Agents for Atrial Fibrillation in Cancer Patients
In a recent article in the journal, Patell et  al1 found CHADS2 (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism) and CHA2DS2VASC (congestive heart failure, hypertension, age ≥ 75, diabetes mellitus, prior stroke/transient ischemic attack/thromboembolism, vascular disease, age 65-74, sex category [i.e., female]) to predict risk of ischemic stroke in cancer patients with baseline atrial fibrillation (AF). Although only 36% of patients received anticoagulant therapy, the risk of stroke generally appeared to be lower than in cancer-free individuals.
Source: The American Journal of Cardiology - February 3, 2018 Category: Cardiology Authors: Marc Sorigue, Edurne Sarrate, Mireia Franch-Sarto, Mireia Santos-Gomez, Elisa Orna Source Type: research

Homocysteine-lowering interventions for preventing cardiovascular events.
CONCLUSIONS: This updated Cochrane review found no evidence to suggest that homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination should be used for preventing cardiovascular events. Furthermore, there is no evidence suggesting that homocysteine-lowering interventions are associated with an increased risk of cancer. PMID: 23440809 [PubMed - in process]
Source: Cochrane Database of Systematic Reviews - March 2, 2013 Category: Journals (General) Authors: Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D Tags: Cochrane Database Syst Rev Source Type: research

Effects of Habitual Coffee Consumption on Cardiometabolic Disease, Cardiovascular Health, and All-cause Mortality: O'Keefe JH, Bhatti SK, Patil HR. J Am Coll Cardiol 2013;62:1043−51.
This study examines existing data regarding coffee consumption and its effect on health and all-cause mortality. Coffee consumption confers a benefit in the reduction of Type II diabetes mellitus (T2DM). There was significant reduction in a dose-dependent relationship of coffee consumption and reduction of T2DM. Caffeinated and noncaffeinated beverages confer the same benefit. The authors conclude that coffee's effect on serum lipids is a dose-dependent increase in serum total cholesterol and a nonsignificant increase in low-density lipoprotein concentrations in only boiled preparations of coffee, but not for filtered coff...
Source: The Journal of Emergency Medicine - April 24, 2014 Category: Emergency Medicine Authors: Java Tunson Tags: Abstracts Source Type: research

Health care costs for prostate cancer patients receiving androgen deprivation therapy: treatment and adverse events.
CONCLUSIONS: The economic burden of adverse events is relevant to programs and policies from clinic to government, and that burden merits consideration in the risks and benefits of adt. PMID: 24940106 [PubMed]
Source: Current Oncology - November 19, 2014 Category: Cancer & Oncology Tags: Curr Oncol Source Type: research

Homocysteine-lowering interventions for preventing cardiovascular events.
CONCLUSIONS: This second update of this Cochrane Review found no evidence to suggest that homocysteine-lowering interventions in the form of supplements of vitamins B6, B9 or B12 given alone or in combination should be used for preventing cardiovascular events. Furthermore, there is no evidence to suggest that homocysteine-lowering interventions are associated with an increased risk of cancer. PMID: 25590290 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - January 15, 2015 Category: Journals (General) Authors: Martí-Carvajal AJ, Solà I, Lathyris D Tags: Cochrane Database Syst Rev Source Type: research

Diabetes drug pioglitazone could get personal: Neither panacea, nor peril
When I was in training, one of my beloved mentors declared, “I never use a drug until it’s been on the market for 20 years.” I was young enough then that I couldn’t fathom being a doctor for 20 years, let alone waiting two decades to use a new drug. As my career has progressed, I’ve seen many new drugs released to the market. Some of them are truly miraculous, bringing people longer, healthier, and more productive lives. Many of them have not withstood the test of time. More than a few have even been taken off the market. Even though the Food and Drug Administration diligently reviews each new medicine before it...
Source: New Harvard Health Information - May 5, 2016 Category: Consumer Health News Authors: Lori Wiviott Tishler, MD, MPH Tags: Diabetes Drugs and Supplements pioglitazone thiazolidinediones Source Type: news

Prevalence of Atrial Fibrillation and Antithrombotic Therapy in Hemodialysis Patients: Cross-Sectional Results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIalysis (VIVALDI)
ConclusionsThe prevalence of AF is high amongst HD patients and is associated with age, sex, and distinct comorbidities. Practice patterns of antithrombotic treatment indicate a lack of consensus for stroke prevention in HD patients with AF.
Source: PLoS One - January 3, 2017 Category: Biomedical Science Authors: Oliver K önigsbrügge Source Type: research